HRP20150927T1 - Sastav nosaäśa za brzu isporuku nukleinske kiseline - Google Patents
Sastav nosaäśa za brzu isporuku nukleinske kiseline Download PDFInfo
- Publication number
- HRP20150927T1 HRP20150927T1 HRP20150927TT HRP20150927T HRP20150927T1 HR P20150927 T1 HRP20150927 T1 HR P20150927T1 HR P20150927T T HRP20150927T T HR P20150927TT HR P20150927 T HRP20150927 T HR P20150927T HR P20150927 T1 HRP20150927 T1 HR P20150927T1
- Authority
- HR
- Croatia
- Prior art keywords
- sirna
- composition
- ingredient
- delivery
- cholesterol
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 12
- 239000004615 ingredient Substances 0.000 claims 10
- 235000012000 cholesterol Nutrition 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 3
- -1 aliphatic primary amine Chemical class 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (12)
1. Sastav za isporuku siRNK, koji sadrži siRNK i sastav nosača za isporuku siRNK, naznačen time, da obuhvaća (A) diacilfosfatidilkolin, (B) najmanje jedan član odabran iz skupine koju čine kolesterol i kationski lipidi koji imaju kolesterolski kostur, i (C) alifatski primarni amin.
2. Sastav za isporuku siRNK prema zahtjevu 1, naznačen time, da sastojak (A) je diacilfosfatidilkolin čiji dio acilne skupine ima 4 do 23 atoma ugljika.
3. Sastav za isporuku siRNK prema zahtjevu 1 ili 2, naznačen time, da sastojak (B) je kolesterol.
4. Sastav za isporuku siRNK prema bilo kojem od zahtjeva 1 do 3, naznačen time, da sastojak (C) je alkilamin koji ima 10 do 20 atoma ugljika.
5. Sastav za isporuku siRNK prema zahtjevu 1, naznačen time, da sastojak (A) je najmanje jedan član odabran iz skupine koju čine dimiristoilfosfatidilkolin, dipalmitoilfosfatidilkolin, i distearoilfosfatidilkolin;
sastojak (B) je kolesterol; i
sastojak (C) je stearilamin.
6. Sastav za isporuku siRNK prema bilo kojem od zahtjeva 1 do 5, naznačen time, da molarni odnos za sastojak (A) : sastojak (B) : sastojak (C) odgovara za 5-9 : 1-5 : 1.
7. Sastav za isporuku siRNK prema bilo kojem od zahtjeva 1 do 6, naznačen time, da sastav nosača za isporuku siRNK je liposomski pripravak u kojem je liposomska membrana stvorena od sastojaka (A) do (C).
8. Sastav za isporuku siRNK prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je to liposomski pripravak.
9. Sastav prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava kao lijek.
10. Sastav prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u inhibiciji ekspresije ciljanog gena u stanicama koje postoje u živim organizmima.
11. Uporaba sastava nosača koji sadrži (A) diacilfosfatidilkolin, (B) najmanje jedan član odabran iz skupine koju čine kolesterol i kationski lipidi koji imaju kolesterolski kostur, i (C) alifatski primarni amin te siRNK, naznačena time, da je za proizvodnju sastava prema bilo kojem od zahtjeva 1 do 10.
12. Postupak za uvođenje siRNK, naznačen time, da obuhvaća korak uvođenja siRNK u kultivirane stanice ili stanice odvojene od živih organizama, pomoću dovođenja u doticaj sastava za isporuku siRNK prema zahtjevu 1, sa stanicama.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007079944 | 2007-03-26 | ||
| PCT/JP2008/055730 WO2008117828A1 (ja) | 2007-03-26 | 2008-03-26 | 即効型核酸送達用キャリアー組成物 |
| EP08738918.5A EP2140870B1 (en) | 2007-03-26 | 2008-03-26 | Prompt nucleic acid delivery carrier composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150927T1 true HRP20150927T1 (hr) | 2015-10-09 |
Family
ID=39788561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150927TT HRP20150927T1 (hr) | 2007-03-26 | 2015-09-03 | Sastav nosaäśa za brzu isporuku nukleinske kiseline |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9315828B2 (hr) |
| EP (1) | EP2140870B1 (hr) |
| JP (1) | JP5349293B2 (hr) |
| KR (1) | KR101459391B1 (hr) |
| CN (1) | CN101646443B (hr) |
| AR (1) | AR065847A1 (hr) |
| AU (1) | AU2008230379B2 (hr) |
| BR (1) | BRPI0809634A2 (hr) |
| CA (1) | CA2682490A1 (hr) |
| CO (1) | CO6241127A2 (hr) |
| DK (1) | DK2140870T3 (hr) |
| ES (1) | ES2542864T3 (hr) |
| HK (1) | HK1139041A1 (hr) |
| HR (1) | HRP20150927T1 (hr) |
| HU (1) | HUE027053T2 (hr) |
| IL (1) | IL201116A0 (hr) |
| MX (1) | MX2009010336A (hr) |
| MY (1) | MY151450A (hr) |
| NZ (1) | NZ579804A (hr) |
| PL (1) | PL2140870T3 (hr) |
| PT (1) | PT2140870E (hr) |
| RU (1) | RU2476229C2 (hr) |
| SI (1) | SI2140870T1 (hr) |
| TW (1) | TWI428135B (hr) |
| UA (1) | UA97143C2 (hr) |
| WO (1) | WO2008117828A1 (hr) |
| ZA (1) | ZA200906576B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2542874T3 (es) * | 2009-03-04 | 2015-08-12 | Hirofumi Takeuchi | Complejo de ácidos nucleicos y composición de administración de ácidos nucleicos |
| WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
| ES2888231T3 (es) | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| JP6029131B2 (ja) * | 2011-12-28 | 2016-11-24 | 国立研究開発法人国立循環器病研究センター | 核酸導入剤、核酸導入方法及び細胞 |
| CN110582302A (zh) | 2016-12-14 | 2019-12-17 | 利甘达尔股份有限公司 | 用于核酸和/或蛋白有效负载递送的组合物和方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776488A (en) * | 1994-03-11 | 1998-07-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Liposome preparation |
| US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| US6126964A (en) * | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
| US6358523B1 (en) * | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| US6835395B1 (en) * | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
| JPH10313872A (ja) * | 1997-05-21 | 1998-12-02 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス剤 |
| CA2303366A1 (en) * | 1997-09-16 | 1999-03-25 | Nexstar Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
| US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
| JPH11292795A (ja) | 1998-04-02 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | Ｈｉｖコファクター抑制剤 |
| US7166745B1 (en) | 1998-11-12 | 2007-01-23 | Invitrogen Corporation | Transfection reagents |
| EP1317281A1 (fr) * | 2000-09-08 | 2003-06-11 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
| US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
| WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| CN100488491C (zh) * | 2002-11-21 | 2009-05-20 | 派维翁生物技术有限公司 | 高效融合小泡,其制备方法和含有该小泡的药物组合物 |
| US20040208921A1 (en) * | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| KR20060036060A (ko) * | 2003-06-27 | 2006-04-27 | 스미또모 가가꾸 가부시키가이샤 | 아미드 화합물 및 이를 사용한 식물 병해의 방제 방법 |
| ES2559828T3 (es) * | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| DK1663315T3 (da) * | 2003-09-17 | 2011-04-18 | Rodos Biotarget Gmbh | Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller |
| EP1759691A1 (en) | 2003-11-20 | 2007-03-07 | Delex Therapeutics Inc. | Stable liposome compositions |
| AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
| JP2005336081A (ja) * | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| EP1773857A4 (en) | 2004-07-02 | 2009-05-13 | Protiva Biotherapeutics Inc | THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF |
| AU2005306533B2 (en) * | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
| US9006487B2 (en) * | 2005-06-15 | 2015-04-14 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| WO2007048019A2 (en) * | 2005-10-20 | 2007-04-26 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| UA97559C2 (uk) | 2007-11-08 | 2012-02-27 | Оцука Фармасьютікал Ко., Лтд. | Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти |
-
2008
- 2008-03-25 TW TW097110544A patent/TWI428135B/zh not_active IP Right Cessation
- 2008-03-26 DK DK08738918.5T patent/DK2140870T3/en active
- 2008-03-26 AU AU2008230379A patent/AU2008230379B2/en not_active Ceased
- 2008-03-26 HU HUE08738918A patent/HUE027053T2/en unknown
- 2008-03-26 US US12/532,949 patent/US9315828B2/en not_active Expired - Fee Related
- 2008-03-26 NZ NZ579804A patent/NZ579804A/en not_active IP Right Cessation
- 2008-03-26 MY MYPI20093905 patent/MY151450A/en unknown
- 2008-03-26 RU RU2009139246/15A patent/RU2476229C2/ru not_active IP Right Cessation
- 2008-03-26 AR ARP080101222A patent/AR065847A1/es unknown
- 2008-03-26 CN CN200880010035.6A patent/CN101646443B/zh not_active Expired - Fee Related
- 2008-03-26 WO PCT/JP2008/055730 patent/WO2008117828A1/ja active Application Filing
- 2008-03-26 KR KR1020097021571A patent/KR101459391B1/ko not_active IP Right Cessation
- 2008-03-26 JP JP2009506363A patent/JP5349293B2/ja active Active
- 2008-03-26 UA UAA200910735A patent/UA97143C2/ru unknown
- 2008-03-26 PT PT87389185T patent/PT2140870E/pt unknown
- 2008-03-26 CA CA002682490A patent/CA2682490A1/en not_active Abandoned
- 2008-03-26 MX MX2009010336A patent/MX2009010336A/es active IP Right Grant
- 2008-03-26 ES ES08738918.5T patent/ES2542864T3/es active Active
- 2008-03-26 EP EP08738918.5A patent/EP2140870B1/en active Active
- 2008-03-26 SI SI200831495T patent/SI2140870T1/sl unknown
- 2008-03-26 PL PL08738918T patent/PL2140870T3/pl unknown
- 2008-03-26 BR BRPI0809634-1A2A patent/BRPI0809634A2/pt not_active IP Right Cessation
-
2009
- 2009-09-21 ZA ZA2009/06576A patent/ZA200906576B/en unknown
- 2009-09-23 IL IL201116A patent/IL201116A0/en unknown
- 2009-10-26 CO CO09120191A patent/CO6241127A2/es active IP Right Grant
-
2010
- 2010-05-14 HK HK10104730.5A patent/HK1139041A1/xx not_active IP Right Cessation
-
2015
- 2015-09-03 HR HRP20150927TT patent/HRP20150927T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150927T1 (hr) | Sastav nosaäśa za brzu isporuku nukleinske kiseline | |
| CN109475640B (zh) | 核酸被运载物的混合载运体 | |
| US20190381180A1 (en) | Hybrid carriers for nucleic acid cargo | |
| JP2020202826A (ja) | コードされている病原体抗原の発現を増加させるための、ヒストンステムループとポリ（ａ）配列又はポリアデニル化シグナルとを含むか又はコードしている核酸 | |
| JP2023166400A5 (hr) | ||
| HK1245325A1 (zh) | 用於誘導外顯子跳躍的反義寡核苷酸及其使用方法 | |
| WO2008089771A8 (en) | Dna controlled assembly of lipid membranes | |
| EP2810661A3 (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids | |
| WO2014162307A3 (en) | Methods and apparatus for synthesizing nucleic acids | |
| TW200642700A (en) | Chemically defined stabiliser | |
| JP2009519339A5 (hr) | ||
| CN103153347A (zh) | 用于寡核苷酸递送的新型低分子量阳离子脂质 | |
| NI201000104A (es) | SALES FARMACEUTICAMENTE ACEPTABLES DE (3-{[[3-(6-AMINO-2-BUTOXI-8- 0X0-7,8-DIHIDRO-9H-PURIN-9-lL) PROPIL] (3-MORFOLIN-4-lLPROPIL) AMINOWETIL} FENIL) ACETATO DE METILO Y SUS USOS EN TERAPIA. | |
| RU2016103695A (ru) | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ | |
| WO2010056043A3 (en) | Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same | |
| ES2249293T5 (es) | Secuencias de nucleótidos para el gen TAL | |
| WO2003057164A3 (en) | Compounds for delivering substances into cells | |
| WO2011053065A3 (ko) | 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법 | |
| WO2005086896A3 (en) | Delivery vectors for short interfering rna, micro-rna and antisense rna | |
| UA91137C2 (ru) | Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения | |
| ES2427244T3 (es) | Composición farmacéutica con contenido en una L-ribozima para el tratamiento de efectos secundarios mediante la administración de espiegelmeros | |
| WO2009148955A3 (en) | Multi-arm amines and uses thereof | |
| EP2851426A3 (en) | Compositions and methods for inhibiting expression of RRM2 genes | |
| WO2009129523A3 (en) | Compositions and methods for nucleic acid delivery | |
| MX2011011395A (es) | Composiciones y metodos para inhibir la expresion de genes de receptor de glucocorticoide. |